AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Sanofi","sponsor":"Cellectis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectis and Sanofi Partner on Alemtuzumab as Lymphodepletion Agent for Allogeneic CAR-T","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellectis","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cellectis Enters Into Warrant Agreement with The European Investment Bank Related to Credit Facility Agreement and Announces the Drawdown of The First Tranche of 20 Million","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi's Alemtuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals for Alemtuzumab

    Menu

    Alemtuzumab

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Sanofi

              Contact Supplier
              • Deals
              Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
              Contact Supplier Contact Supplier
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellectis and Sanofi Partner on Alemtuzumab as Lymphodepletion Agent for Allogeneic CAR-T

              Details:

              In Cellectis sponsored trials, alemtuzumab is currently used as part of the lymphodepleting regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory ALL, and for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, but not for UCARTCS1.

              Lead Product(s): UCART22,Alemtuzumab

              Therapeutic Area: Oncology Product Name: UCART22

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Cellectis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 11, 2021

              Sanofi Company Banner

              78th STLE Annual Meeting

              Not Confirmed

              envelop Contact Supplier

              Cellectis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi's Alemtuzumab

              Details:

              UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

              Lead Product(s): UCART22,Alemtuzumab

              Therapeutic Area: Oncology Product Name: UCART22

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 24, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cellectis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cellectis Enters Into Warrant Agreement with The European Investment Bank Related to Credit Facility Agreement and Announces the Drawdown of The First Tranche of 20 Million

              Details:

              The Company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.

              Lead Product(s): UCART22,Alemtuzumab

              Therapeutic Area: Oncology Product Name: UCART22

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: European Investment Bank

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement April 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY